Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Objective:
The primary objective of the study is to evaluate the effect of R-mabHDI in patients with
late stage, widespread stage and recurrent Lymphocytic Predominant Hodgkin's Lymphoma.
The hypothesis is that the combination of R-mabHDI with the standard ABVD therapy in patients
with late stage (Stage III and Stage IV) and recurrent stage Lymphocytic Predominant
Hodgkin's Lymphoma will have a favorable outcome on the response and progress free survival.
The study is also aimed at evaluating the safety of R-mabHDI .
The aim of the study is to test this hypothesis by evaluating the clinical outcome in 1200
patients receiving combination of R-mabHDI once a week for 8 weeks and ABVD therapy every
other week for 12 treatments.
Phase:
Phase 3
Details
Lead Sponsor:
American Scitech International
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company ImClone LLC